Abstract 4368353: ALDH2 rs671 polymorphism and metabolic signatures in patients with cardiovascular diseases

Object: Aldehyde dehydrogenase 2 (ALDH2) rs671 polymorphism is an established genetic risk of hypertension, diabetes, and coronary heart diseases in Asian population. However, clinically, the association between ALDH2 polymorphism and metabolic signatures, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) remains unknown. We aim to investigate the relationship between ALDH2 rs671 polymorphism and metabolic signatures, providing early warning of metabolic syndromes based on ALDH2 genotyping. Method: A total of 200 patients were included between 2017 and 2020. The patients were divided into three groups according to their ALDH2 rs671 genotyping, AA (n=46), GA (n=83), and GG (n=71). Categorical data are presented as frequency and percentage. Continuous variables are reported as median and interquartile range (IQR). A one-way analysis of variance (ANOVA) or chi-squared test was performed as appropriate for intergroup comparison. Result: There were little differences among three groups of patients with regard to sex and age. Our result revealed that ALDH2 AA genotype (mutant homozygotes) exhibited a higher risk of hypertension than other groups (P=0.034, using a chi-square test). Furthermore, patients with ALDH2 AA genotype tended to have a habit of smoking (P=0.047, using a chi-square test), while they were less likely to drink (P=0.008, using a chi-square test). Speaking of metabolic signatures, ALDH2 AA genotype displayed lower TG (P=0.023, using a one-way ANOVA) and higher HDL (P=0.041, using a one-way ANOVA), with no significant influence on TC and LDL. Conclusion: This study revealed that ALDH2 rs671 polymorphism has an influence on certain metabolic signatures, including hypertension, smoke, drink, CG and HDL, indicating ALDH2 genotyping could be applied as a potential biomarker in metabolic syndromes.